We use third-party cookies to provide support. By continuing to browse this website,
you accept our privacy policy.
Heron Therapeutics Inc
10 own
25 watching
Current Price
$2.79
$0.19
(7.31%)
1 Week Returns
3 Months Returns
1 Year Returns
Get Started with as little as $1.00
Market Capitalization
331.38M
52-Week High
9.45
52-Week Low
2.19
Average Volume
2.18M
Dividend Yield
--
P/E Ratio
--
Market Capitalization331.38M52-Week High9.4552-Week Low2.19Average Volume2.18MDividend Yield--P/E Ratio--What does the Heron Therapeutics Inc do?
Heron Therapeutics, Inc., a biotechnology company, develops products to address unmet medical needs using its proprietary Biochronomer polymer-based drug delivery platform in the United States. Its drug delivery platform is designed to enhance the therapeutic profile of injectable pharmaceuticals. The company's lead product candidate includes SUSTOL (granisetron injection, extended release), which is in Phase III clinical trial for the prevention of acute- and delayed-onset chemotherapy-induced nausea and vomiting. It is also developing HTX-011 that is in Phase I clinical trial for the management of post-operative pain; HTX-019, an injectable neurokinin-1 receptor antagonist for the prevention of chemotherapy induced nausea and vomiting; and HTX-003, a formulation of buprenorphine for the management of chronic pain and opioid addiction. The company was formerly known as A.P. Pharma, Inc. and changed its name to Heron Therapeutics, Inc. in January 2014. Heron Therapeutics, Inc. was founded in 1983 and is headquartered in Redwood City, California.
Read More
How much money does Heron Therapeutics Inc make?
News & Events about Heron Therapeutics Inc.
PR Newswire
20days ago
Heron Therapeutics Highlights Progress in Acute Care and Oncology Care Franchises Heron Therapeutics Highlights Progress in Acute Care and Oncology Care Franchises PR Newswire SAN DIEGO, Jan. 9, 2023 - Preliminary Annual Net Product Sales Across the Company Grew 24% to $106.7 Million in 2022...
PR Newswire
1month ago
Heron Therapeutics Announces Filing of an Efficacy Supplement for ZYNRELEF and Provision in Newly Passed Congressional Bill Anticipated to Provide Separate Reimbursement Outside of the Packaged Surgical Payment for ZYNRELEF Heron Therapeutics Announces Filing of an Efficacy Supplement for ZYNRELEF...
Ticker Report
5 months ago
Heron Therapeutics (NASDAQ:HRTX Get Rating) had its target price decreased by Cowen to $5.50 in a research note issued to investors on Monday morning, Stock Target Advisor reports. Several other brokerages have also weighed in on HRTX. Cowen decreased their price objective on Heron ...
Ticker Report
5 months ago
New York State Common Retirement Fund increased its stake in Heron Therapeutics, Inc. (NASDAQ:HRTX Get Rating) by 0.6% in the first quarter, according to the company in its most recent Form 13F filing with the Securities Exchange Commission. The fund owned 807,503 shares of the ...
Frequently Asked Questions
Frequently Asked Questions
What is Heron Therapeutics Inc share price today?
Can Indians buy Heron Therapeutics Inc shares?
How can I buy Heron Therapeutics Inc shares from India?
Can Fractional shares of Heron Therapeutics Inc be purchased?
What are the documents required to start investing in Heron Therapeutics Inc stocks?
What is today’s traded volume of Heron Therapeutics Inc?
What is today’s market capitalisation of Heron Therapeutics Inc?
What is the 52-Week High and Low Range of Heron Therapeutics Inc?
What percentage is Heron Therapeutics Inc down from its 52-Week High?
What percentage is Heron Therapeutics Inc up from its 52-Week Low?
Current Price
$2.79
$0.19
(7.31%)
1 Week Returns
3 Months Returns
1 Year Returns
Get Started with as little as $1.00
Related Stocks
Sign up and dive into a whole new world of investing.
Join over 280,000 who have signed up and are using Stockal successfully already.
Related Stocks
Sign up and dive into a whole new world of investing.
Join over 280,000 who have signed up and are using Stockal successfully already.